Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Including Bone and Soft Tissue Sarcoma, Melanoma, Liver Cancer, Esophageal Cancer, Breast Cancer, Thyroid Cancer and Ovarian Cancer

Trial Profile

Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Including Bone and Soft Tissue Sarcoma, Melanoma, Liver Cancer, Esophageal Cancer, Breast Cancer, Thyroid Cancer and Ovarian Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs TAEST 16001 (Primary) ; Cyclophosphamide; Interleukin-2
  • Indications Bladder cancer; Bone cancer; Breast cancer; Liver cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Prostate cancer; Soft tissue sarcoma; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top